These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 10977391)

  • 1. Mirtazapine. A pharmacoeconomic review of its use in depression.
    Holm KJ; Jarvis B; Foster RH
    Pharmacoeconomics; 2000 May; 17(5):515-34. PubMed ID: 10977391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
    Brown MC; Nimmerrichter AA; Guest JF
    Eur Psychiatry; 1999 Jul; 14(4):230-44. PubMed ID: 10572352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK.
    Borghi J; Guest JF
    Eur Psychiatry; 2000 Sep; 15(6):378-87. PubMed ID: 11004733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirtazapine: a review of its use in major depression.
    Holm KJ; Markham A
    Drugs; 1999 Apr; 57(4):607-31. PubMed ID: 10235695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C
    J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine. A pharmacoeconomic review of its use in depression.
    Wilde MI; Benfield P
    Pharmacoeconomics; 1998 May; 13(5 Pt 1):543-61. PubMed ID: 10180753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the pharmacological and clinical profile of mirtazapine.
    Anttila SA; Leinonen EV
    CNS Drug Rev; 2001; 7(3):249-64. PubMed ID: 11607047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data.
    Kasper S
    Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():25-35. PubMed ID: 8930007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does mirtazapine have a more rapid onset than SSRIs?
    Quitkin FM; Taylor BP; Kremer C
    J Clin Psychiatry; 2001 May; 62(5):358-61. PubMed ID: 11411818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
    Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
    CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine.
    Kasper S
    J Clin Psychopharmacol; 1997 Apr; 17 Suppl 1():19S-28S. PubMed ID: 9090574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirtazapine: a review of its use in major depression and other psychiatric disorders.
    Croom KF; Perry CM; Plosker GL
    CNS Drugs; 2009; 23(5):427-52. PubMed ID: 19453203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
    Bateman DN; Chick J; Good AM; Kelly CA; Masterton G
    Eur J Clin Pharmacol; 2004 May; 60(3):221-4. PubMed ID: 15083251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
    Pallanti S; Quercioli L; Bruscoli M
    J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
    Hong CJ; Hu WH; Chen CC; Hsiao CC; Tsai SJ; Ruwe FJ
    J Clin Psychiatry; 2003 Aug; 64(8):921-6. PubMed ID: 12927007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.